Entrada Therapeutics Management
Management criteria checks 4/4
Entrada Therapeutics' CEO is Dipal Doshi, appointed in Aug 2017, has a tenure of 7.33 years. total yearly compensation is $3.74M, comprised of 15.7% salary and 84.3% bonuses, including company stock and options. directly owns 0.35% of the company’s shares, worth $2.16M. The average tenure of the management team and the board of directors is 3.7 years and 3.8 years respectively.
Key information
Dipal Doshi
Chief executive officer
US$3.7m
Total compensation
| CEO salary percentage | 15.7% |
| CEO tenure | 7.3yrs |
| CEO ownership | 0.3% |
| Management average tenure | 3.7yrs |
| Board average tenure | 3.8yrs |
Recent management updates
Recent updates
There Is A Reason Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Price Is Undemanding
Oct 17
Analysts' Revenue Estimates For Entrada Therapeutics, Inc. (NASDAQ:TRDA) Are Surging Higher
Aug 23Entrada Therapeutics: A Complicated Tale
Jun 16Entrada Therapeutics, Inc.'s (NASDAQ:TRDA) Shares Bounce 30% But Its Business Still Trails The Industry
May 29These Analysts Just Made A Massive Downgrade To Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) EPS Forecasts
Mar 19This Just In: Analysts Are Boosting Their Entrada Therapeutics, Inc. (NASDAQ:TRDA) Outlook for Next Year
Nov 09Need To Know: Analysts Are Much More Bullish On Entrada Therapeutics, Inc. (NASDAQ:TRDA)
May 26Earnings Miss: Entrada Therapeutics, Inc. Missed EPS And Analysts Are Revising Their Forecasts
May 14Will Entrada Therapeutics (NASDAQ:TRDA) Spend Its Cash Wisely?
Mar 08We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
Sep 11Entrada Therapeutics GAAP EPS of -$0.74 misses by $0.02
Aug 11We're Not Very Worried About Entrada Therapeutics' (NASDAQ:TRDA) Cash Burn Rate
May 28We Think Entrada Therapeutics (NASDAQ:TRDA) Can Afford To Drive Business Growth
Jan 31CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$55m |
| Jun 30 2024 | n/a | n/a | US$104m |
| Mar 31 2024 | n/a | n/a | US$23m |
| Dec 31 2023 | US$4m | US$585k | -US$7m |
| Sep 30 2023 | n/a | n/a | -US$22m |
| Jun 30 2023 | n/a | n/a | -US$82m |
| Mar 31 2023 | n/a | n/a | -US$80m |
| Dec 31 2022 | US$3m | US$565k | -US$95m |
| Sep 30 2022 | n/a | n/a | -US$88m |
| Jun 30 2022 | n/a | n/a | -US$78m |
| Mar 31 2022 | n/a | n/a | -US$64m |
| Dec 31 2021 | US$6m | US$425k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$41m |
| Jun 30 2021 | n/a | n/a | -US$34m |
| Mar 31 2021 | n/a | n/a | -US$29m |
| Dec 31 2020 | US$906k | US$385k | -US$27m |
Compensation vs Market: Dipal's total compensation ($USD3.74M) is about average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Dipal's compensation has been consistent with company performance over the past year.
CEO
Dipal Doshi (48 yo)
7.3yrs
Tenure
US$3,735,466
Compensation
Mr. Dipal Doshi serves as Director of The Children's Health Fund. He serves as Director of Ashibio, Inc since September 2024. Mr. Doshi has been Chief Executive Officer and Director of Entrada Therapeutics...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.3yrs | US$3.74m | 0.35% $ 2.2m | |
| President & COO | 5.1yrs | US$1.49m | 0.35% $ 2.2m | |
| President of Research & Development | less than a year | US$1.49m | 0.20% $ 1.2m | |
| CFO & Treasurer | 4.1yrs | no data | 0.21% $ 1.3m | |
| General Counsel | 4.7yrs | no data | no data | |
| Senior Vice President of People | 3.3yrs | no data | no data | |
| Chief Corporate Affairs Officer | 2.4yrs | no data | no data | |
| Senior Vice President of Regulatory Affairs | less than a year | no data | no data |
3.7yrs
Average Tenure
50.5yo
Average Age
Experienced Management: TRDA's management team is considered experienced (3.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | 7.3yrs | US$3.74m | 0.35% $ 2.2m | |
| Director | 4yrs | US$192.12k | 0.29% $ 1.8m | |
| Industry Leader & Independent Director | 3.6yrs | US$211.18k | 0% $ 0 | |
| Independent Chairman of the Board | 8.2yrs | US$237.58k | 0% $ 0 | |
| Industry Leader & Independent Director | 1.7yrs | US$334.02k | 0% $ 0 | |
| Independent Director | 1.3yrs | US$341.88k | 0% $ 0 |
3.8yrs
Average Tenure
58.5yo
Average Age
Experienced Board: TRDA's board of directors are considered experienced (3.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 07:30 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Entrada Therapeutics, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Chris Shibutani | Goldman Sachs |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Boobalan Pachaiyappan | H.C. Wainwright & Co. |